Biotech entity
Of the tracked stories, 3 of 5 also mention Wall Street Zen, the most common co-covered peer. The clearest coverage concentration is pharma: 3 of 5 stories, with the rest divided among 1 other category. Negative sentiment reaches 0% here, compared with 19% across the 551-story beat baseline for the same window.
Last mentioned: Sep 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 5 also mention Wall Street Zen, the most common co-covered peer. The clearest coverage concentration is pharma: 3 of 5 stories, with the rest divided among 1 other category. Negative sentiment reaches 0% here, compared with 19% across the 551-story beat baseline for the same window. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. They are less corroborated than the beat average, carrying 2.2 original sources each against 3.5 for the same window. Across a 182-day span, the pace is roughly 0.2 stories per week. This profile follows 5 Biotech stories mentioning Bank of America across the period from March 12, 2026 to September 9, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 551 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bank of America. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen rating actions
Wall Street Zen upgraded Tenaya from strong sell to sell and argenx from hold to buy.
Deutsche Bank downgrades argenx
Deutsche Bank cut argenx from buy to hold.
Truist raises argenx target
Truist Financial lifted its argenx target from $1,030.00 to $1,095.00 with a buy rating.
Tenaya Q2 miss
Tenaya reported EPS of -$0.20 versus -$0.07 expected and revenue of $1.11 million versus $10 million consensus.
Weiss Ratings upgrades Tenaya
Weiss Ratings moved Tenaya from sell (e+) to sell (d-), still within sell territory.
Baird raises argenx target
Robert W. Baird raised argenx target from $867.00 to $932.00 with a neutral rating.
argenx Q2 beat
argenx reported EPS of $7.32 versus $5.86 expected and revenue of $1.54 billion.
BofA lifts argenx target
Bank of America raised its price objective on argenx from $1,016.00 to $1,088.00 with a buy rating.
BofA Price Target Hike
Bank of America increases price target, highlighting R&D productivity and MedTech growth.
Fast-Track Approval
USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.
12-Month High
JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.
Wall Street Zen upgraded Tenaya from strong sell to sell, but the micro-cap gene therapy company still trades near a 52-week low after a sharp Q2 EPS and revenue miss. Biotech readers get a closer look at how clinical-stage execution failures are reflected in rating actions, while argenx's profitable rare disease business shows what commercial success looks like.
Source: tickerreport.com · dailypolitical.com
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Source: tickerreport.com · themarketsdaily.com
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Source: dailypolitical.com · tickerreport.com
REGENXBIO Chief Medical Officer Steve Pakola offloaded 56,333 shares for $688,756 following a disastrous Q1 miss, but analysts maintain price targets implying up to 99% upside. The insider sales add tension to a gene therapy story already defined by high risk and potential reward.
Source: Zolmax · Markets Daily
Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.
Bank of America is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
